Hypodermic Needles and Syringes

BD Hypodermic Syringe Shortage Resolution Delayed to August 31, 2026

July 31 Section 232 Effective Date and Stacked 100% Section 301 Tariffs Target Delivery Inputs

BD Insulin Syringe Line Re-Branded to Embecta Effective July 1, 2026

Section 232 Tariff Enforcement Set for July 31, 2026

FDA Updates Import Alerts 89-08 and 99-34 Restricting Unregistered Syringe Imports (July 2026)

July 31, 2026 Section 232 Tariffs Target Foreign Syringes and Injectable Platforms

FDA maintains active shortages for specialized angiographic and biopsy needle devices

July 2026 trade policies impose effective duty rates above 40%–50% on Chinese delivery supplies

July 2026: USTR Proposes New Section 301 Tariffs Affecting Medical Supplies

U.S. Section 301 and Delivery Component Tariffs Reaching 100% on July 31, 2026